|
릴게임알라딘 7.rkp925.top 바로가기 야마토게임기, 야마토5
야마토릴게임바다이야기 먹튀 돈 받기야마토게임 다운로드손오공 릴게임
무료머니릴게임 44.rkp925.top 무료게임다운로드
체리마스터 51.rkp925.top 신천지3.0
온라인야마토2 8.rkp925.top 황금성나비
바다이야기슬롯 57.rkp925.top 모바일야마토게임
바다이야기환전가능 88.rkp925.top 릴게임횡금성
인터넷황금성 37.rkp925.top 알라딘게임예시
무료충전릴게임 68.rkp925.top 한게임바둑이게임
바다이야기게임다운로드 4.rkp925.top 바다이야기 예시
바다이야기 슬롯 2.rkp925.top 릴예시게임
황금성 무료머니 37.rkp925.top 바다신2영상 야마토노하우 바다이야기5 릴게임알라딘 릴게임골드몽사이트 인터넷바다이야기게임 릴게임손오공 전함야마토 야마토5게임공략법 오락실게임 파라다이스 황금성 릴게임가입머니 릴게임총판 바다이야기조작 야마토2동영상 오리자날 양귀비 오션파라 다이스게임 하는법 야마토게임방법 바다게임이야기 릴게임매장 이벤트릴게임 알라딘온라인릴게임 오리지널바다이야기 릴게임판매 슬롯사이트 황금성2 오션파라다이스7게임 신천지무료 바다이야기파칭코 바다이야기게임하는곳 야마토3게임공략법 오락실릴게임 실시간바둑이 슬롯 잘 터지는 바나나게임 릴게임판매 프라그마틱 순위 최신야마토게임 야마토카지노 게임바둑이추천 져스트릴게임 릴게임 5만 메타슬롯 바다이야기파칭코 야마토게임장주소 바다이야기상어 카지노 슬롯머신 잭팟 카카오릴게임 무료게임 슬롯커뮤니티 바다슬롯먹튀 다빈치다운로드 모바일릴게임 손오공바다이야기 릴게임임대 릴게임 다빈치 온라인 슬롯 하는 법 온라인신천지 릴게임보물섬 알라딘오락실 슬롯머신게임 야마토3동영상 야마토2게임동영상 바다이야기 2화 슬롯머신무료 용의 눈 게임 바다이야기파칭코 슬롯머신 확률 모바일릴게임접속하기 체리마스터 다운 바다이야기무료머니 최신바다게임 바다이야기 모바일 바다이야기 게임장 황금성게임공략방법 야마토게임장 우주전함야마토먹튀 신천지게임사이트 무료슬롯머신 바다이야기 조작 프라그마틱환수율 야마토예시 오션파라 다이스7 온라인야마토주소 모바일릴게임접속하기 야마토예시 카지노 슬롯머신 잭팟 모바일 릴게임 알라딘온라인릴게임 릴게임 다운로드 야마토 게임방법 야마토게임다운 모바일릴게임접속하기 스톰게임 황금성갈가리 카지노 슬롯머신 규칙 모바일릴게임 종류 도그하우스 하는법 체리마스터 공략 바다이야기릴게임사이트추천및안내 황금성다운 바다이야기 사이트 먹튀 바다이야기 상어 바다이야기 예시 바다이야기 하는법 사이다쿨게임 바다이야기7 황금성 제주도 릴게임사이트 무료 황금성게임 야마토5게임방법 오션파라 다이스7 모바일오션 파라 다이스7 야마토게임공략법 PC 슬롯 머신 게임 바다이야기게임하는방법 백경다운로드 바다이야기 무료게임 바둑이넷마블 뽀빠이놀이터릴게임 백경게임공략방법 바다이야기무료머니 릴게임횡금성 릴게임먹튀검증 슬롯머신 규칙 오션릴게임 This article was released as Pharm Edaily Premium Content on October 26, 2025, at 12:31 PM.
[Kim Jiwan, Edaily Reporter] On October 24, Korea’s biotech market saw a surge in activity, driven by a string of positive developments in antibody-drug conjugate (ADC) and anticancer drug programs.
INTOCELL jumped sharply after resolving its patent dispute. Genome 직장인 신용대출 서류 & Company extended gains ahead of global data disclosure for its new ADC candidate, and HLB Life Science rallied after its liver cancer trial results were published in the world-renowned medical jour 농협변동금리 nal The Lancet, boosting overall investor sentiment across related stocks.
INTOCELL gains momentum after patent dispute resolved
INTOCELL continued its upward momentum after recen 우체국카드 t news that its collaboration with Samsung Bioepis had been reinforced and its ADC-related patent dispute resolved.
According to KG Zeroin’s MP Doctor (formerly Market Point), INTOCELL close 차할부금조회 d at \48,150, up \2,850 (15.59%) from the previous session.
Tae-Kyo Park, CEO of INTOCELL (Photo = Saemi Kim, Edaily)
Sa 신용회복자대출가능한곳 msung Bioepis announced on the 21st that it had signed a joint research and exclusive license agreement with Chinese biotech company Frontline Biopharma to collaborate on antibody-drug conjugate (ADC) candidates. This deal effectively resolved the patent controversy surrounding INTOCELL’s core technology, “Nexatecan3.”
Frontline Biopharma, which possesses a bispecific antibody, dual payload ADC platform, is recognized as an emerging innovator in the oncology field. Under this agreement, Samsung Bioepis obtained exclusive rights to apply one of Frontline’s payload technologies, the cytotoxic component responsible for killing cancer cells, to its own development pipeline.
The issue stemmed from the fact that this payload technology was closely related to INTOCELL’s Nexatecan3, which had previously raised concerns about possible patent overlap. INTOCELL had signed a technology partnership with Samsung Bioepis in December 2023, providing its proprietary OPAS linker platform and payload technology. The two companies have since been collaborating to develop and evaluate up to five ADC candidates targeting various cancers.
However, market uncertainty lingered over potential patent infringement involving Nexatecan, and the controversy deepened when Abybel Bio terminated its technology licensing agreement with INTOCELL in July. With this new Samsung Bioepis?Frontline deal, however, concerns about INTOCELL’s patent risks appear to be resolved.
Samsung Bioepis also announced plans to jointly develop two ADC pipelines with Frontline, with “TJ108” as the first candidate. TJ108 is a dual-target ADC based on topoisomerase I and tubulin inhibitors, designed to attack both EGFR and HER3?targets commonly overexpressed in multiple solid tumors?to maximize therapeutic efficacy.
An industry official commented, “By reinforcing its partnership with Samsung Bioepis and clearing patent uncertainties, INTOCELL has regained technological credibility and is now positioned to accelerate its R&D in the ADC field.”
Genome & Company rises on anticipation of data disclosure
Genome & Company’s shares climbed on growing investor optimism as the firm prepares to unveil preclinical data for its next-generation ADC candidate, GENA-120, on the global stage.
The stock closed at \2,755, up \95 (3.57%) from the previous day.
A Genome & Company researcher conducts an experiment. (Photo provided by Genome & Company)
The company announced it will participate in the World ADC San Diego conference, held from November 3~6 (local time) in the United States, where it plans to present preclinical data for GENA-120 and discuss potential strategic collaborations with global pharma partners.
As one of the largest ADC-focused events, World ADC gathers over 1,000 global researchers, biotech firms, and investors to discuss the latest ADC technologies and commercialization strategies. Genome & Company will showcase key preclinical data demonstrating GENA-120’s anti-tumor activity and its novel target’s expression profile.
GENA-120 targets GICP-120, a new cancer biomarker discovered through Genome & Company’s AI-driven drug discovery platform, GNOCLE™. Research results show that GICP-120 is highly expressed in multiple solid tumors?including head and neck, cervical, colorectal, esophageal, and gastric cancers? but rarely found in normal tissues. The company will also present data confirming GENA-120’s strong anti-tumor efficacy in preclinical models.
Hong You-seok, Co-CEO of Genome & Company, said, “Our presentation at World ADC will showcase GENA-120’s global potential,” adding that the company “will continue to share key pipeline data at major international conferences and pursue tangible milestones such as technology licensing.”
HLB Life Science sustains gains on The Lancet publication
HLB Life Science extended its rally following the publication of clinical trial results for its liver cancer drug in The Lancet.
The stock closed at \4,485, up \615 (15.59%), after hitting an intraday high of \4,530.
The rally followed HLB’s announcement that its combination therapy of rivoceranib and camrelizumab had demonstrated over twofold improvement in disease-free survival (DFS) compared with surgery alone in patients with resectable hepatocellular carcinoma (HCC).
This marks the first clinical validation of the rivoceranib camrelizumab combination in early and intermediate-stage HCC, expanding its potential beyond previously confirmed efficacy in advanced liver cancer. The study was conducted by China’s Jiangsu Hengrui Medicine, involving 294 patients across 16 hospitals.
An HLB spokesperson said, “This outcome provides a strong foundation to extend the combination therapy strategy across the entire treatment spectrum of liver cancer.”
김지완 (2pac@edaily.co.kr)
|
